GPCRs market comprises assays and kits that aid in drug discovery and development. GPCRs is a large family of cell surface receptors that respond to a diverse range of external stimulus and play a major role in modern pharmacology due to their significant function in cell communication. More than 30% of the drugs available in the global market target GPCRs and most of the drugs that are currently under clinical and preclinical studies target this highly studied receptor protein. A wide range of GPCR assays such as cAMP assays, calcium level detection assays, etc. have been developed over the years that have helped in drug discovery processes worldwide.
The global GPCRs market has been categorized based on six assay types: calcium level detection assays, GTPγS binding assays, cGMP assays, reporter gene assays, receptor internalization assays, and cAMP assays. The cAMP assays segment held the largest share of the market, followed by the calcium level detection assays segment in 2013. Key factors attributed to the high growth of this segment are increasing demand for cAMP assays in high throughput screening (HTS) and various other major drug discovery platforms, introduction of advanced cAMP assays and wide applicability of these assays in a range of therapeutic applications.
In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Oncology was the largest segment of the global GPCRs market in 2013. The segment includes several prime cancer therapeutic areas such as breast cancer, leukemia, lung cancer, cervical cancer, prostate cancer, and/or several other malignant tumorous outgrowths. High prevalence and increasing incidence of several of these cancers are expected to drive the growth of the segment in the near future.
Geographically, the GPCRs market has been categorized into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global GPCRs market followed by Europe owing to high geriatric population and rising obesity-related diseases due to unhealthy lifestyle habits, unhealthy eating habits, excessive alcohol intake and smoking leading to cardiovascular diseases. The regions also account for high number of research and development activities for the development of highly effective therapeutic drugs, which would require increased usage of GPCR assays. Asia Pacific was the third largest market for GPCRs, and is expected to register the fastest CAGR during the forecast period. Large untapped opportunities, improving health care infrastructure, rising research and development activities, expansion of large pharmaceutical manufacturers and CROs, and rising geriatric population in the region would contribute to the growth of the market.
Thermo Fisher Scientific, Inc., EMD Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd. are the major players operating in the global GPCRs market. Most of these players constantly innovate and develop technologically advanced and/or improved GPCR assays and assay systems to maintain their positions in the global market. For instance, Tango GPCR Assay System and GeneBLAzer Validated Functional Assays from Thermo Fisher Scientific, Inc., ACTOne cAMP Assay from Becton, Dickinson and Company and Cyclic AMP cell-based assay kits from Cisbio Bioassays, would help in capitalizing on future customer preferences. These market players also collaborate with other companies as well as various global organizations through long-term agreements to develop innovative, technologically advanced or improved GPCR assays, assay platforms and systems.